Susquehanna Fundamental Investments LLC Takes $11.39 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Susquehanna Fundamental Investments LLC bought a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the second quarter, Holdings Channel reports. The institutional investor bought 106,750 shares of the specialty pharmaceutical company’s stock, valued at approximately $11,393,000.

Other large investors also recently modified their holdings of the company. Capital World Investors purchased a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $171,943,000. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $106,936,000. Vestal Point Capital LP purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $89,175,000. Rubric Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter valued at approximately $65,812,000. Finally, Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. UBS Group decreased their price target on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research report on Tuesday, July 2nd. Robert W. Baird decreased their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Piper Sandler decreased their target price on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Insider Activity at Jazz Pharmaceuticals

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $110.93 on Friday. The stock has a market cap of $7.00 billion, a PE ratio of 22.87, a price-to-earnings-growth ratio of 1.36 and a beta of 0.57. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The company has a debt-to-equity ratio of 1.36, a quick ratio of 2.02 and a current ratio of 2.37. The stock has a fifty day moving average of $111.02 and a 200-day moving average of $110.82.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, beating the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. Equities research analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.